Comparative performances of HIV-1 RNA load assays at low viral load levels: Results of an international collaboration

Journal of Clinical Microbiology

Volumn 52, Issue 2, 2014, Pages 517-523

  Swenson, Luke C ^a   Cobb, Bryan ^b   Geretti, Anna Maria ^c   Harrigan, P Richard ^a   Poljak, Mario ^d   Seguin Devaux, Carole ^e   Verhofstede, Chris ^f   Wirden, Marc ^g   Amendola, Alessandra ^h   Boni, Jurg ⁱ   Bourlet, Thomas ^j   Huder, Jon B ⁱ   Karasi, Jean Claude ^k   Lepej, Snjezana Zidovec ^l   Lunar, Maja M ^d   Mukabayire, Odette ^k   Schuurman, Rob ^m   Tomažič, Janez ^d   Van Laethem, Kristel ⁿ   Vandekerckhove, Linos ^f   Wensing, Annemarie M J ^m   more..

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b ROCHE MOLECULAR SYSTEMS   (United States)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

^e LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^f GHENT UNIVERSITY   (Belgium)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

ⁱ UNIVERSITY OF ZURICH   (Switzerland)

^j UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^k National Reference Laboratory   (Rwanda)

^l Croatia   (Croatia)

^m UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁿ REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ANALYTICAL PARAMETERS; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FUNCTION TEST KIT; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERASSAY CONCORDANCE; INTERMETHOD COMPARISON; INTERNATIONAL COOPERATION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LOW LEVEL VIREMIA; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; VIREMIA; VIRUS DETECTION; VIRUS EXAMINATION; VIRUS LOAD; VIRUS LOAD ASSAY;

HIV INFECTIONS; HIV-1; HUMANS; INTERNATIONAL COOPERATION; PLASMA; RNA, VIRAL; VIRAL LOAD;

EID: 84893124451     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02461-13     Document Type: Article

References (48)

1. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. 2012. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308:387-402. http://dx.doi.org/10.1001/jama.2012.7961.
2. Sun R, Ku J, Jayakar H, Kuo JC, Brambilla D, Herman S, Rosenstraus M, Spadoro J. 1998. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 36:2964-2969.
3. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson M, Khoo S, Leen C, Marshall N, Nelson M, Orkin C, Paton N, Phillips A, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski A, Walsh J, Waters L, Wilkins E, Winston A, Youle M. 2012. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 13:1-85. http://dx.doi.org/10.1111/j.1468-1293.2012. 01029.x.
4. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. 2032. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services, Washington, DC. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
5. EACS. 2012. Guidelines version 6.1. European AIDS Clinical Society, Paris, France. http://www.sm.ee/fileadmin/meedia/Dokumendid/Tervisevaldkond/ Tervishoid/EACSGuidelines-v6.1-Nov2012.pdf.
6. Naeth G, Ehret R, Wiesmann F, Braun P, Knechten H, Berger A. 2013. Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia. Med. Microbiol. Immunol. 202:67-75. http://dx.doi.org/10.1007/s00430-012-0249-y.
7. Schutten M, Peters D, Back NK, Beld M, Beuselinck K, Foulongne V, Geretti AM, Pandiani L, Tiemann C, Niesters HG. 2007. Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J. Clin. Microbiol. 45:1712-1717. http://dx.doi.org/10.1128/JCM.02385-06.
8. Wall GR, Perinpanathan D, Clark DA. 2012. Comparison of the QIAGEN artus HIV-1 QS-RGQ test with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0. J. Clin. Virol. 55:62-66. http://dx.doi.org/10.1016/j.jcv.2012.05.014.
9. Garcia-Diaz A, Labbett W, Clewley GS, Guerrero-Ramos A, Geretti AM. 2013. Comparative evaluation of the Artus HIV-1 QS-RGQ assay and the Abbott RealTime HIV-1 assay for the quantification of HIV-1 RNA in plasma. J. Clin. Virol. 57:66-69. http://dx.doi.org/10.1016/j.jcv.2013.01.006.
10. Oliver AR, Pereira SF, Clark DA. 2007. Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche AMPLICOR version 1.5 conventional PCR assay. J. Clin. Microbiol. 45:3616-3619. http://dx.doi.org/10.1128/JCM.00221-07.
11. Lima V, Harrigan R, Montaner JSG. 2009. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J. Acquir. Immune Defic. Syndr. 51:3-6. http://dx.doi.org/10.1097/QAI.0b013e31819e721b.
12. Szabo S, Moffett LE, Cantwell-McNelis K, James CW, Joseph A. 2010. Low-level viremia associated with the use of TaqMan assay. J. Int. Assoc. Physicians AIDS Care (Chic.) 9:203-205. http://dx.doi.org/10.1177/ 1545109710371131.
13. Geretti AM, Tong W, Fox Z, Labbett W, O'Shea S, Chrystie I, Smit E. 2009. The Roche Cobas? AmpliPrep/Cobas TaqMan HIV-1 Version 2.0 Assay for HIV-1 RNA Load Measurement in Plasma Shows Improved Detection of Non-B Subtypes and Increased Levels of Detection and Reporting. Abstr. PE20.6/1. HIV Med. 10(Suppl 2):220. http://dx.doi.org/10.1111/j.1468-1293.2009.00792.x.
14. Gatanaga H, Tsukada K, Honda H, Tanuma J, Yazaki H, Watanabe T, Honda M, Teruya K, Kikuchi Y, Oka S. 2009. Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clin. Infect. Dis. 48:259-260. http://dx.doi.org/10.1086/595706.
15. Yan CS, Hanafi I, Kelleher AD, Carr AD, Amin J, McNally LP, Cunningham PH. 2010. Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification. J. Clin. Virol. 49:249-253. http://dx.doi.org/10.1016/j.jcv.2010.08.016.
16. Ruelle J, Debaisieux L, Vancutsem E, De Bel A, Delforge ML, Piérard D, Goubau P. 2012. HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability. BMC Infect. Dis. 12:100. http://dx.doi.org/10.1186/1471-2334-12-100.
17. Amendola A, Milia MG, Ghisetti V, Brega C, Zaccaro P, Capobianchi MR. 2009. Accuracy of A Commercial Real-time Polymerase Chain Reaction-Based System for Measurement of HIVRNAlevels Around the Limit of Quantification of the Assay. Clin. Infect. Dis. 48:1630-1631; Author Reply 1631-1632. http://dx.doi.org/10. 1086/598990.
18. Damond F, Roquebert B, Bénard A, Collin G, Miceli M, Yéni P, Brun-Vezinet F, Descamps D. 2007. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche Cobas AMPLICOR HIV-1 MONITOR version 1.5 and the Roche Cobas AmpliPrep/ Cobas TaqMan HIV-1 assays. J. Clin. Microbiol. 45:3436-3438. http://dx.doi.org/10.1128/JCM.00973-07.
19. Karasi JC, Dziezuk F, Quennery L, Fösrster S, Reischl U, Colucci G, Schoener D, Seguin-Devaux C, Schmit JC. 2011. High correlation between the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1, version 2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes. J. Clin. Virol. 52:181-186. http://dx.doi.org/10.1016/j.jcv.2011.07.002.
20. Bourlet T, Signori-Schmuck A, Roche L, Icard V, Saoudin H, Trabaud M-A, Tardy J-C, Morand P, Pozzetto B, Ecochard R, André P. 2011. HIV-1 load comparison using four commercial real-time assays. J. Clin. Microbiol. 49:292-297. http://dx.doi.org/10.1128/JCM.01688-10.
21. Jennings C, Harty B, Granger S, Wager C, Crump JA Fiscus SA, Bremer JW. 2012. Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation. J. Clin. Microbiol. 50:2737-2747. http://dx.doi.org/10.1128/JCM.00578-12.
22. Verhofstede C, Van Wanzeele F, Van Der Gucht B, Pelgrom J, Vandekerckhove L, Plum J, Vogelaers D. 2007. Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1, 000 RNA copies/ml. J. Med. Virol. 79:1254-1260. http://dx.doi.org/10.1002/jmv.20950.
23. Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, Phillips AN, Geretti AM. 2012. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin. Infect. Dis. 54:724-732. http://dx.doi.org/10.1093/cid/cir936.
24. Delaugerre C, Gallien S, Flandre P, Mathez D, Amarsy R, Ferret S, Timsit J, Molina J-M, de Truchis P. 2012. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PLoS One 7:e36673. http://dx.doi.org/10.1371/journal.pone.0036673.
25. Cohen Stuart JW, Wensing AM, Kovacs C, Righart M, de Jong D, Kaye S, Schuurman R, Visser CJ, Boucher CA. 2001. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J. Acquir. Immune Defic. Syndr. 28:105-113. http://dx.doi.org/10.1097/00126334- 200110010-00001.
26. Henrich TJ, Wood BR, Kuritzkes DR. 2012. Increased risk of virologic rebound in patients on antiviral therapy with isolated detectable viral loads-48 copies/mL by Taqman RT-PCR assay. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, Sitges, Spain.
27. Alvarez M, Chueca N, Guillot V, Pena A, Munoz LP, Hernandez-Quero J, Garcia F. 2012. Plasma HIV-1 viral load below 50 using the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test (Roche) is also associated to a higher risk of virologic rebound. Abstr. O-23. European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, Barcelona, Spain.
28. Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, Gregis G, Quinzan G, Soavi L, Iannotti N, Malfatto E, Leone S. 2012. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J. Acquir. Immune Defic. Syndr. 60:473-482. http://dx.doi.org/10.1097/QAI.0b013e3182567a57.
29. Harrigan R, Sherlock C, Hogg RS, Wynhoven B, Chui C, Swenson L, Lima VD, Montaner J. 2011. What should be the primary virological endpoint in clinical trials of ARV efficacy? Abstr. 661. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA.
30. Manavi K. 2008. The significance of low-level plasma HIV viral load on Cobas TaqMan HIV-1 assays for patients with undetectable plasma viral load on Cobas Amplicor monitor version 1.5. HIV Clin. Trials 9:283-286. http://dx.doi.org/10.1310/hct0904-283.
31. Brumme CJ, Swenson LC, Wynhoven B, Yip B, Skinner S, Lima VD, Montaner JSG, Harrigan PR. 2012. Technical and regulatory shortcomings of the TaqMan version 1 HIV viral load assay. PLoS One 7:e43882. http://dx.doi.org/10.1371/ journal.pone.0043882.
32. Charpentier C, Landman R, Laouenan C, Joly V, Hamet G, Damond F, Brun-Vezinet F, Mentre F, Descamps D, Yeni P. 2012. Virological outcome of patients displaying persistent low-level viremia comprised between 20 and 50 copies/mL. Abstr. 349. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA.
33. Montaner J, British Columbia Centre for Excellence in HIV/AIDS Therapeutic Guidelines Committee. 2011. Therapeutic guidelines: antiretroviral treatment (ARV) of adult HIV infection. BC Centre for Excellent in HIV/AIDS, Vancouver, British Columbia, Canada. http://www.cfenet.ubc.ca/sites/default/ files/uploads/BCCfE%20Adult%20Therapeutic%20Guidelines-Jan2011.pdf.
34. Verhofstede C, Van Wanzeele F, Reynaerts J, Mangelschots M, Plum J, Fransen K. 2010. Viral load assay sensitivity and low level viremia in HAART treated HIV patients. J. Clin. Virol. 47:335-339. http://dx.doi.org/10.1016/j. jcv.2010.01.008.
35. Wirden M, Tubiana R, Marguet F, Leroy I, Simon A, Bonmarchand M, Ait-Arkoub Z, Murphy R, Marcelin AG, Katlama C, Calvez V. 2009. Impact of discrepancies between the Abbott RealTime and Cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group Mnon-B subtypes. J. Clin. Microbiol. 47:1543-1545. http://dx.doi.org/10.1128/JCM.02134-08.
36. Wirden M, Tubiana R, Fourati S, Thevenin M, Simon A, Canestri A, Ait-Arkoub Z, Soulie C, Marcelin AG, Katlama C, Calvez V. 2011. Upgraded Cobas AmpliPrep-Cobas TaqMan version 2.0 HIV-1 RNA quantification assay versus first version: correction of underestimations. J. Clin. Microbiol. 49:2700-2702. http://dx.doi.org/10.1128/JCM.00061-11.
37. Adachi D, Benedet M, Tang JWT, Cloherty G. 2013. Comparative evaluation of plasma preparation tube (PPT) and EDTA samples using Roche's Cobas TaqMan HIV-1 and Abbott's RealTime HIV-1 v. 4.00 assays, poster TUPE262. 7th IAS Conference on HIV Pathogenesis and Treatment. Kuala Lumpur, Malaysia, 30 June to 3 July 2013.
38. Sloma CR, Germer JJ, Gerads TM, Mandrekar JN, Mitchell PS, Yao JDC. 2009. Comparison of the Abbott RealTime human immunodeficiency virus type 1 (HIV-1) assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 test: workflow, reliability, and direct costs. J. Clin. Microbiol. 47: 889-895. http://dx.doi.org/10.1128/JCM. 02231-08.
39. Garrett NJ, Apea V, Nori A, Ushiro-Lumb I, Oliver AR, Baily G, Clark DA. 2012. Comparison of the rate and size of HIV-1 viral load blips with Roche Cobas TaqMan HIV-1 versions 1.0 and 2.0 and implications for patient management. J. Clin. Virol. 53:354-355. http://dx.doi.org/10.1016/j.jcv.2011.12.024.
40. Taylor N, Grabmeier-Pfistershammer K, Egle A, Greil R, Rieger A, Ledergerber B, Oberkofler H. 2013. Cobas AmpliPrep/Cobas TaqMan HIV-1 version 2.0 assay: consequence at the cohort level. PLoS One 8:e74024. http://dx.doi.org/10.1371/journal.pone.0074024.
41. Willig JH, Nevin CR, Raper JL, Saag MS, Mugavero MJ, Willig AL, Burkhardt JH, Schumacher JE, Johnson VA. 2010. Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 version 1.0 viral load test. J. Acquir. Immune Defic. Syndr. 54:442-444. http://dx.doi.org/10.1097/QAI.0b013e3181d01d1d.
42. Paba P, Fabeni L, Ciccozzi M, Perno CF, Ciotti M. 2011. Performance evaluation of the Cobas/TaqMan HIV-1 v2.0 in HIV-1 positive patients with low viral load: a comparative study. J. Virol. Methods 173:399-402. http://dx.doi.org/10.1016/j.jviromet.2011.03.014.
43. Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, Hare CB, Deeks SG, Liegler T, Pandori M, Havlir DV, Wong JK. 2011. Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. J. Virol. Methods 175:261-265. http://dx.doi.org/10.1016/j.jviromet. 2011.04.015.
44. Hilldorfer BB, Cillo AR, Besson GJ, Bedison MA, Mellors JW. 2012. New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond. Curr. HIV/AIDS Rep. 9:91-100. http://dx.doi.org/10.1007/s11904-011-0104- 6.
45. Palmer S, Wiegand AP, Maldarelli F, Mican JM, Polis M, Dewar RL, Planta A, Liu S, Metcalf JA, Mellors JW, Coffin JM. 2003. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41:4531-4536.
46. Amendola A, Bloisi M, Marsella P, Sabatini R, Bibbò A, Angeletti C, Capobianchi MR. 2011. Standardization and performance evaluation of "modified" and "ultrasensitive" versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia. J. Clin. Virol. 52:17-22 http://dx.doi.org/10.1016/j.jcv.2011.04.012.
47. Grgic I, Zidovec Lepej S, Vince A, Begovac J. 2010. Increased frequency of viral loads above 100, 000 HIV-1 RNA copies/ml measured by Roche Cobas TaqMan assay in comparison with Cobas Amplicor assay. J. Clin. Virol. 48:75-76. http://dx.doi.org/10.1016/j.jcv.2010.02.009.
48. Rebeiro PF, Kheshti A, Bebawy SS, Stinnette SE, Erdem H, Tang YW, Sterling TR, Raffanti SP, D'Aquila RT. 2008. Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. Clin. Infect. Dis. 47:1354-1357. http://dx.doi.org/10.1086/592693.